← All trials
NCT06079788
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2023
- Primary completion
- Jun 30, 2026
- Completion date
- Dec 31, 2026
- First posted
- Oct 12, 2023
- Last posted
- Oct 12, 2023
- Enrollment
- 140
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Zhejiang UniversityLead sponsor
- Nanjing Medical UniversityCollaborator
- Kunming Medical UniversityCollaborator
- Ningbo Women & Children's HospitalCollaborator
- Zhejiang UniversitySponsor investigator
- Huazhong University of Science and TechnologyCollaborator
- Jiao Tong UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.